TherapeuticsMD (TXMD) Net Cash Flow (2010 - 2026)

TherapeuticsMD (TXMD) has reported Net Cash Flow for 17 consecutive years, with $779000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 104.46% year-over-year to $779000.0; the trailing twelve-month figure through Jun 2026 stood at $3.1 million (up 201.85% YoY), and the FY2025 full-year result was $2.5 million, up 109.74% from the prior year.
• Net Cash Flow slipped to $779000.0 in Q2 2026 per TXMD's latest filing, from $944000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $19.5 million in Q3 2022 and bottomed at -$140.8 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$13.4 million across 5 years, with a median of -$27000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow plunged 437.54% in 2022, then soared 2105.88% in 2025.
• Over 5 years, Net Cash Flow stood at -$81.8 million in 2022, then soared by 96.38% to -$3.0 million in 2023, then surged by 100.57% to $17000.0 in 2024, then jumped by 2105.88% to $375000.0 in 2025, then surged by 107.73% to $779000.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $779000.0, $944000.0, and $375000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.